Wave Life Sciences Slips as Obesity Data Fails to Convince

6 days ago 6

Joel South

Fri, March 27, 2026 astatine 9:00 AM CDT 4 min read

Wave Life Sciences (WVE) shares fell astir 50% to $6.20 aft BofA and Wells Fargo chopped terms targets to $21 and $13 respectively, citing insufficient information for WVE-007 arsenic a standalone obesity attraction and reduced condemnation successful the liver Activin E knockdown mechanism.
The INLIGHT proceedings showed 14.3% placebo-adjusted visceral abdominous simplification with preserved thin muscle, but the Phase 1 cohort included lower-BMI patients than emblematic obesity studies, leaving monotherapy efficacy unproven successful the colonisation astir apt to benefit.
Have You work The New Report Shaking Up Retirement Plans? Americans are answering 3 questions and galore are realizing they tin discontinue earlier than expected.

Wave Life Sciences (NASDAQ:WVE) shares are trading adjacent historical lows aft 2 Wall Street firms chopped their terms targets pursuing updated Phase 1 INLIGHT proceedings information for WVE-007, the company's obesity candidate.

The banal fell astir 50% connected March 26, closing astatine $6.20 — its lowest level successful implicit a twelvemonth — arsenic investors concluded the information fell abbreviated of what would beryllium needed to found WVE-007 arsenic a standalone obesity therapy. So acold this year, shares of WVE are down much than 60%

Ticker

Firm

Rating

Old Target

New Target

Key Concern

WVE	BofA	Buy	$38	$21	Monotherapy grounds gap
WVE	Wells Fargo	Overweight	$27	$13	Liver Activin E knockdown conviction

BofA lowered its terms people to $21 from $38 portion maintaining a Buy rating, arguing that much grounds is needed to person investors of WVE-007's imaginable — peculiarly arsenic a monotherapy. The steadfast inactive sees accidental successful higher BMI patients and successful operation with incretins oregon arsenic a post-incretin attraction treatment.

Have You work The New Report Shaking Up Retirement Plans? Americans are answering 3 questions and galore are realizing they tin retire earlier than expected.

Wells Fargo chopped its people to $13 from $27, keeping an Overweight rating, but flagged reduced condemnation that Activin E knockdown successful the liver volition reliably thrust meaningful abdominous loss, citing the 400mg cohort information specifically. The firm's interest centers connected whether the mechanics translates into clinically applicable value simplification astatine the doses tested truthful far.

The INLIGHT interim readout reported a 14.3% placebo-adjusted simplification successful visceral abdominous six months aft a azygous dose, alongside preservation of thin musculus wide — a differentiated illustration compared to GLP-1 therapies that often trim musculus alongside fat. Earlier cohort information showed up to 85% mean Activin E simplification astatine the 400mg dose, yet the market's absorption suggests people suppression of the biomarker did not construe into the fat-loss magnitude investors were pricing in.

Read Entire Article